Actinium Pharmaceuticals, Inc. (ATNM) Corporate Subsidiaries
Actinium Pharmaceuticals, Inc. (ATNM) is a publicly traded company on the NYSE, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: ATNM
CIK: 1388320
Exchange: NYSE
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
CBIZ CPAs P.C.
Auditor SinceSince 12/31/2025 12:00:00 AM
Lead Engagement PartnerMohammed Asaduzzaman
Audit LocationHouston, Texas, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 4 | 2026-10-16 | 2026-10-14 | 4 Filing | 0001213900-26-110340 | View SEC Doc Filr Page |
| 3 | 2026-10-16 | 2026-10-14 | 3 Filing | 0001213900-26-110337 | View SEC Doc Filr Page |
| ARS | 2026-10-16 | 2025-12-31 | ARS | 0001213900-26-110024 | View SEC Doc Filr Page |
| DEF 14A | 2026-10-16 | 2026-11-25 | PROXY STATEMENT | 0001213900-26-110022 | View SEC Doc Filr Page |
| 8-K | 2026-10-15 | 2026-10-14 | CURRENT REPORT | 0001213900-26-109884 | View SEC Doc Filr Page |
| S-8 | 2026-10-09 | — | REGISTRATION STATEMENT | 0001213900-26-108558 | View SEC Doc Filr Page |
| 3 | 2026-09-10 | 2026-09-03 | 3 Filing | 0001213900-26-098841 | View SEC Doc Filr Page |
| 3 | 2026-09-10 | 2026-09-03 | 3 Filing | 0001213900-26-098842 | View SEC Doc Filr Page |
| 4 | 2026-09-04 | 2026-09-02 | 4 Filing | 0001213900-26-097744 | View SEC Doc Filr Page |
| 4 | 2026-09-04 | 2026-09-02 | 4 Filing | 0001213900-26-097745 | View SEC Doc Filr Page |
| 4 | 2026-09-04 | 2026-09-02 | 4 Filing | 0001213900-26-097742 | View SEC Doc Filr Page |
| 4 | 2026-09-04 | 2026-09-02 | 4 Filing | 0001213900-26-097741 | View SEC Doc Filr Page |
| 4 | 2026-09-04 | 2026-09-02 | 4 Filing | 0001213900-26-097740 | View SEC Doc Filr Page |
| 4 | 2026-09-04 | 2026-09-02 | 4 Filing | 0001213900-26-097739 | View SEC Doc Filr Page |
| 8-K | 2026-08-14 | 2026-08-12 | CURRENT REPORT | 0001213900-26-090232 | View SEC Doc Filr Page |
| 10-Q | 2026-08-07 | 2026-06-30 | QUARTERLY REPORT | 0001213900-26-086769 | View SEC Doc Filr Page |
| 8-K | 2026-06-18 | 2026-06-18 | CURRENT REPORT | 0001213900-26-070193 | View SEC Doc Filr Page |
| 8-K | 2026-05-29 | 2026-05-27 | CURRENT REPORT | 0001213900-26-062935 | View SEC Doc Filr Page |
| 10-Q | 2026-05-08 | 2026-03-31 | QUARTERLY REPORT | 0001213900-26-053980 | View SEC Doc Filr Page |
| 10-K | 2026-03-30 | 2025-12-31 | ANNUAL REPORT | 0001213900-26-036504 | View SEC Doc Filr Page |
| 8-K/A | 2026-03-26 | 2025-11-26 | AMENDMENT NO.1 TO FORM 8-K | 0001213900-26-034807 | View SEC Doc Filr Page |
| 8-K | 2026-02-13 | 2026-02-11 | CURRENT REPORT | 0001213900-26-016559 | View SEC Doc Filr Page |
| 8-K | 2025-11-26 | 2025-11-26 | CURRENT REPORT | 0001213900-25-115586 | View SEC Doc Filr Page |
| 10-Q | 2025-11-14 | 2025-09-30 | QUARTERLY REPORT | 0001213900-25-110979 | View SEC Doc Filr Page |
| ARS | 2025-11-05 | 2024-12-31 | ARS | 0001213900-25-106708 | View SEC Doc Filr Page |